2025 guideline for the management of peritoneal mesothelioma
The guideline recommends a multidisciplinary approach to peritoneal mesothelioma that includes surgery, medical oncology, radiology, pathology, and social work to improve patient outcomes and incorporate clinical trial enrollment at every treatment stage.
This consensus guideline summarizes best practices for diagnosis, treatment, and follow‑up of peritoneal mesothelioma (PeM), emphasizing multidisciplinary care, psychosocial support, and enrollment in clinical trials. Recommendations include imaging with CT/MRI, laparoscopic biopsy, histologic subtype assessment, and risk‑stratified systemic therapy (pemetrexed‑based chemotherapy or immune checkpoint inhibition). Cytoreductive surgery plus intraperitoneal chemotherapy (CRS + IPCT) is advised for resectable disease, with surveillance protocols tailored to disease status.
Because peritoneal mesothelioma is extremely rare, treatment decisions are often based on limited evidence; this guideline provides a structured, evidence‑informed framework that can standardize care, enhance survival, and improve quality of life for patients while encouraging participation in trials to advance knowledge.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma